Compare MREO & LFT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MREO | LFT |
|---|---|---|
| Founded | 2015 | 2012 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Real Estate Investment Trusts |
| Sector | Health Care | Real Estate |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 52.5M | 68.1M |
| IPO Year | 2017 | N/A |
| Metric | MREO | LFT |
|---|---|---|
| Price | $0.33 | $1.28 |
| Analyst Decision | Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $1.50 | N/A |
| AVG Volume (30 Days) | ★ 1.4M | 137.9K |
| Earning Date | 05-12-2026 | 05-11-2026 |
| Dividend Yield | N/A | ★ 17.05% |
| EPS Growth | ★ 16.67 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $500,000.00 | N/A |
| Revenue This Year | $6,000.20 | $668.15 |
| Revenue Next Year | $34.71 | N/A |
| P/E Ratio | ★ N/A | $13.49 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $1.18 |
| 52 Week High | $2.94 | $2.71 |
| Indicator | MREO | LFT |
|---|---|---|
| Relative Strength Index (RSI) | 40.25 | 47.84 |
| Support Level | $0.32 | $1.26 |
| Resistance Level | $0.42 | $1.43 |
| Average True Range (ATR) | 0.02 | 0.07 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 29.29 | 64.29 |
Mereo BioPharma Group PLC is a United Kingdom (U.K.) based biopharmaceutical company focused on the development of therapeutics for rare diseases. The company has developed a portfolio of late-stage clinical product candidates, and its two rare disease product candidates are setrusumab for the treatment of osteogenesis imperfecta (OI) and alvelestat, mainly for the treatment of severe alpha-1 antitrypsin deficiency-associated lung disease (AATD-LD).
Lument Finance Trust Inc operates as a real estate investment trust. The company is engaged in investment, financing, and management of a portfolio of commercial real estate debt investments. It invests in transitional floating-rate commercial real estate mortgage loans, mezzanine loans, preferred equity, commercial mortgage-backed securities, fixed-rate loans, construction loans, and other CRE debt instruments.